Pharming

• On 15 December 2024, Pharming (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announced a public cash offer to the shareholders of Abliva (STO: ABLI)
• Abliva shareholders are envisaged to receive SEK 0.45 for each outstanding share in Abliva, bringing the total consideration for Abliva to approximately SEK 725 million
• Undertakings to accept the offer have been obtained from the three largest shareholders, accounting for c. 50% of Abliva's outstanding shares
• With the proposed acquisition of Abliva, Pharming aims to accelerate the development of KL1333, a promising treatment for mitochondrial diseases, enhancing their pipeline of transformative rare disease medicines. This intended strategic acquisition underscores Pharming’s commitment to bring innovative solutions to patients and its vision to become a leading global rare disease company of choice for patients and partners
• Van Lanschot Kempen is acting as Sole Financial Adviser to Pharming providing a repeat client with broad support based on extensive experience in the Nordic life sciences ecosystem, one of Van Lanschot Kempen’s key focus markets

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercialising and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia Pacific.